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A B S T R A C T
Purpose
Standard of care treatment for most stage I rectal cancers is total mesorectal excision (TME).
Given the morbidity associated with TME, local excision (LE) for early-stage rectal cancer has been
explored. This study examines practice patterns and overall survival (OS) for early-stage rec-
tal cancer.
Methods
All patients in the National Cancer Data Base diagnosed with rectal cancer from 1998 to 2010 were
initially included. Use of LE versus proctectomy and use of adjuvant radiation therapy were
compared over time. Adjusted Cox proportional hazards models were used to compare OS based
on treatment.
Results
LE was used to treat 46.5% of patients with T1 and 16.8% with T2 tumors. Use of LE increased
steadily over time (P  .001). LE was most commonly used for women, black patients, very old
patients, those without private health insurance, those with well-differentiated tumors, and those
with T1 tumors. Proctectomy was associated with higher rates of tumor-free surgical margins
compared with LE (95% v 76%; P  .001). Adjuvant radiation therapy use decreased over time
independent of surgical procedure or T stage. For T2N0 disease, patients treated with LE alone
had significantly poorer adjusted OS than those treated with proctectomy alone or multimodal-
ity therapy.
Conclusion
Guideline-concordant adoption of LE for treatment of low-risk stage I rectal cancer is increasing.
However, use of LE is also increasing for higher-risk rectal cancers that do not meet guideline
criteria for LE. Treatment with LE alone is associated with poorer long-term OS. Additional studies
are warranted to understand the factors driving increased use of LE.
J Clin Oncol 31:4276-4282. © 2013 by American Society of Clinical Oncology
INTRODUCTION
The goal of treatment for early-stage rectal cancer is
to optimize oncologic control while minimizing the
long-term impact of treatment on quality of life. The
standard of care treatment for most stage I rectal
cancers is surgery alone, specifically total mesorectal
excision (TME).1 For early rectal cancers, this pro-
cedure is usually curative but can have a substantial
impact on quality of life, including the possibility of
permanent colostomy and the potential for short-
and long-term bowel, bladder, and sexual dysfunc-
tion.2 Given the morbidity associated with TME,
alternative approaches to management of rectal can-
cer have been explored, including local excision (LE)
via transanal excision (TAE) or transanal endo-
scopic microsurgery (TEMS).
Studies have shown that LE alone is inferior
to TME for oncologic control.3,4 The poorer
outcomes associated with LE primarily result
from occult nodal disease, which occurs in ap-
proximately 10% of patients with T1 rectal can-
cers.3 Attempts to identify a subgroup of patients
for whom LE would be safe have led to recom-
mendations from the National Comprehensive
Cancer Network and American Society of Colo-
rectal Surgeons supporting LE as an acceptable
alternative for T1 tumors that are  30% of the
bowel circumference,  3 cm in size, mobile, well
to moderately differentiated, and lack lymphovas-
cular invasion.5-7
Multimodality therapy has also been proposed
as an alternative to TME for patients with rectal
cancer.8,9 Specifically, chemoradiotherapy has been
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added to LE in an attempt to clear subclinical nodal disease. Although
early results are promising, this approach is investigational and has not
been adopted as standard of care.
A 2007 National Cancer Data Base (NCDB) study examining
patterns of surgical care for rectal cancer documented a steady increase
in the use of LE for stage I rectal cancers from 1989 to 2003.10 The
primary goal of this study was to determine whether rates of LE
continue to rise despite a lack of data to support the widespread
adoption of this technique for higher-risk tumors. This study also
examined concomitant trends in the use of adjuvant radiation therapy
for stage I tumors. Finally, long-term overall survival (OS) after LE
versus proctectomy with or without irradiation for early-stage rectal
cancer was examined. Our hypotheses were that use of LE continues to
increase for both well-differentiated T1N0 tumors and for higher-risk
tumors and that patients with stage I rectal cancer treated with LE have
poorer long-term OS than patients treated with proctectomy.6,7
METHODS
The NCDB is a nationwide oncology database that includes incident cases of
cancer from the  1,500 hospitals in the United States with Commission on
Cancer–accredited cancer programs. The database includes approximately
70% of all newly diagnosed cancers in the United States. Variables captured,
including basic demographics, zip code and county-level area characteristics,
tumor staging, initial course of treatment, and vital status, are similar to those
captured by other tumor registry databases, such as the National Cancer
Institute SEER program.
All patients diagnosed with invasive rectal cancer from 1998 to 2010
were initially included. This study period captured a time during which
there were many advances in rectal cancer therapy, such as adoption of
neoadjuvant chemoradiotherapy and development of minimally invasive
transabdominal and transanal surgical techniques. At the time of analysis,
2010 data were the most recent data available. To focus on surgery per-
formed with curative intent, we excluded patient cases for which there was
any indication of distant metastatic disease, those for which tumor staging
information was unknown, and those involving a history of prior malig-
nancy. Similarly, patient cases were excluded if initial chemotherapy, irra-
diation, or surgery was indicated to be administered with palliative intent.
To determine stage, the NCDB analytic stage, which is primarily based on
pathologic tumor stage, was used.11 Patients who underwent neoadjuvant
therapy (chemotherapy and/or radiation therapy before surgical therapy)
were excluded from the main analysis, because pretreatment pathologic
stage could not be determined.
Surgical procedures were defined as proctectomy, LE, or other. Proctec-
tomy included any segmental resection from partial proctectomy to total
abdominal proctocolectomy. Although this group was intended to capture
patients undergoing TME, adoption of TME was ongoing during this study
period, and the completeness of TME could not be verified from registry data.
The LE group included patient cases in which the tumor was removed without
mesenteric resection. Before 2009, the NCDB did not distinguish between
TEMS and traditional TAE. As with proctectomy, the quality of the LE (ie,
depth of excision) could not be verified. The other category included patient
cases in which type of surgical procedure was unknown and those involving
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Fig 1. CONSORT diagram. LE, local
excision.
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any procedure for which a pathology specimen was not generated (eg,
fulgurations, cryoablations, and so on). Patients who underwent these so-
called other procedures were excluded from further analysis.
Logistic and segmented regressions were used to test for differences in
use of LE over time. For stage I tumors, patient and tumor characteristics
associated with procedure type and use of radiation therapy were examined in
bivariate and multivariate analyses. Interactions between T stage and demo-
graphic variables with regard to receipt of LE versus proctectomy were also
examined. Pearson’s 2 test, t test, and multivariate logistic regression analyses
were used to examine differences between the surgical groups. Because few
patients have a comorbidity score (Charlson-Deyo score)  2, the NCDB
reports only three categories (ie, 0, 1,  2). Comorbidity scores were only
available starting in 2003, so a subset analysis was performed for each analysis,
limiting the study population to these more recent patient cases.
In accordance with NCDB participant user file data-use agreements,
survival analysis was limited to patients diagnosed before 2006 to allow for  5
years of follow-up for all patients. Survival was calculated in months from date
of diagnosis to date of last contact or confirmed death. Adjusted Cox propor-
tional hazards models, controlling for patient and tumor characteristics, were
used to compare OS based on treatment received. Given the inherent con-
founding when comparing treatment effectiveness using observational data, a
number of sensitivity analyses were performed to address the effect of design
assumptions on survival outcomes. All statistical analyses were performed
using STATA software (version 11.2; STATA, College Station, TX). Institu-
tional review board exemption was obtained from the University of North
Carolina Institutional Review Board.
RESULTS
A total of 201,764 patients met initial inclusion criteria (Fig 1); 37,062
patients (18%) were excluded because they did not undergo surgery or
because they underwent a surgical procedure that did not meet criteria
as proctectomy or LE. The sequencing of multimodality treatment
evolved over time, with the proportion of patients for whom radiation
was delivered neoadjuvantly increasing from 36.6% in 1998 to 82.8%
in 2010 (P  .001). However, because pretreatment pathologic tumor
stage was not available for patients treated with neoadjuvant therapy,
the 53,249 patients who received neoadjuvant therapy were excluded
from further analysis (Data Supplement).
Of the 111,453 patients remaining after exclusions, 31% were
treated with LE. Of the 2,452 LEs performed in 2010, 60.5% were
performed via TEMS, and 33.7% were performed via traditional TAE;
for 5.8%, surgical approach was unknown. LE was used commonly for
patients with stage I disease (41.2%) and less commonly for those with
stage II disease (7.3%); 46.5% of patients with T1 and 16.8% with T2
tumors were treated with LE. Use of LE increased steadily and statis-
tically significantly over time for every tumor stage group (Fig 2). For
T1 tumors, use of LE increased from 39.8% in 1998 to 62.0% in 2010;
for T2 tumors, use of LE increased from 12.2% to 21.4%.
Among patients with stage I disease, LE was most commonly
used for women, black patients, very old patients, those without pri-
vate health insurance, those with well-differentiated tumors, and those
with T1 tumors (Table 1). In the multivariate analysis, type of proce-
dure was significantly associated with sex, age, race, insurance, educa-
tional attainment, tumor grade, and tumor size. T stage was the factor
most strongly associated with surgical procedure; patients with T2
tumors were much less likely (odds ratio [OR], 0.25; 95% CI, 0.24 to
0.26) to undergo LE compared with patients with T1 tumors. Older
age was associated with use of LE starting at age 70 years compared
with patients age 50 to 59 years. The magnitude of this association was
greater for T1 than for T2 tumors. The interaction between T stage and
age was the only significant interaction. Black patients were more
likely to undergo LE (OR, 1.44; 95% CI, 1.31 to 1.57) than white
patients and uninsured patients were more likely (OR, 1.38; 95% CI,
1.15 to 1.64) than privately insured patients to undergo LE. For the
subset of patients from 2003 to 2010, LE was less common in those
with comorbidity score  2 compared with patients with comorbidity
score of 0 (OR, 0.83; 95% CI, 0.72 to 0.96).
Patients who underwent proctectomy were much more likely
than those who underwent LE to have documented tumor-free final
surgical margins (95% v 76%; P  .001). This was true for both T1 and
T2 tumors.
Adjuvant radiation therapy rates for stage I tumors decreased
over time (Fig 3). In the multivariate analyses, patients who under-
went LE (OR, 4.92; 95% CI, 4.53 to 5.33), those with higher-grade
tumors, those with T2 tumors (OR, 4.10; 95% CI, 3.78 to 4.46), and
those with positive margins (OR, 3.06; 95% CI, 2.69 to 3.49) were most
likely to receive adjuvant radiation (Table 1). Patients age  80 years
were less likely to receive adjuvant radiation. Those with higher co-
morbidity scores were also less likely to receive adjuvant radiation.
For patients treated with LE, unadjusted 30-, 60-, and 90-day
mortality was 0.9%, 1.4%, and 1.9%, compared with 1.5%, 2.1%, and
2.5% for patients treated with proctectomy, respectively. In the mul-
tivariable analysis, increasing age, increasing comorbidity score, and













Stage I local excision
Stage II local excision
T1N0, well/moderately differentiated local excision
T1N0, grade unknown local excision
T1N0, poorly differentiated local excision
T2N0 local excision
A



















Fig 2. Changes in use of local excision (LE) to treat rectal cancer over time
(patients who received neoadjuvant therapy excluded) by (A) disease stage and
(B) subtype of stage I tumors. LE is considered standard-of-care therapy only for
select patients with well or moderately differentiated T1N0 rectal cancers.
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male sex were the only factors associated with increased risk of short-
term death. Notably, there was no difference associated with type
of surgery.
Increasing age, male sex, higher comorbidity score, and positive/
unknown final surgical margins were associated with poorer long-
term adjusted OS (Table 2). Patients with Medicaid and those from
areas with lower high school graduation rates also had poorer OS. For
T1N0 patient cases, there were small but statistically significant differ-
ences in adjusted OS based on treatment approach, with patients
undergoing LE alone or proctectomy plus irradiation having poorer
Table 1. Surgery Type and Adjusted Odds of Receiving LE and Irradiation for Stage I Rectal Cancer (1998-2010 incident cases)
Characteristic
Procedure
LE RTLE (n  18,961)
Proctectomy
(n  27,043)
PNo. % No. % OR 95% CI OR 95% CI
Sex  .001
Male 9,889 39.6 15,095 60.4 1.00 1.00
Female 9,072 43.2 11,948 56.8 1.11 1.05 to 1.16 0.87 0.81 to 0.94
Age, years  .001
 30 98 52.7 88 47.3 1.03 0.70 to 1.51 0.79 0.41 to 1.53
30 to 39 432 43.6 560 56.5 1.01 0.85 to 1.20 1.19 0.94 to 1.52
40 to 49 1,596 39.4 2,459 60.6 1.00 0.91 to 1.10 1.18 1.04 to 1.35
50 to 59 4,155 41.1 5,946 58.9 1.00 1.00
60 to 69 4,510 38.5 7,195 61.5 1.02 0.95 to 1.10 0.96 0.86 to 1.07
70 to 79 4,771 40.1 7,117 59.9 1.22 1.12 to 1.33 0.79 0.70 to 0.90
80 to 89 2,983 46.9 3,381 53.1 1.76 1.59 to 1.94 0.45 0.39 to 0.53
 90 416 58.4 297 41.7 2.78 2.27 to 3.41 0.18 0.11 to 0.29
Race  .001
White 16,146 40.1 24,153 59.9 1.00 1.00
Black 1,793 52.0 1,654 48.0 1.39 1.27 to 1.52 0.98 0.86 to 1.13
Native American 35 34.7 66 65.4 0.76 0.45 to 1.27 0.99 0.47 to 2.05
Asian 568 45.0 695 55.0 0.93 0.80 to 1.08 0.85 0.67 to 1.08
Other/unknown 419 46.9 475 53.1 1.20 1.01 to 1.42 0.73 0.55 to 0.97
Insurance  .001
Uninsured 354 42.9 472 57.1 1.35 1.13 to 1.61 0.83 0.64 to 1.06
Private 2,460 38.5 3,938 61.6 1.00 1.00
Medicaid 502 43.8 643 56.2 1.02 0.87 to 1.20 0.88 0.70 to 1.11
Medicare 9,184 41.2 12,786 58.8 1.01 0.95 to 1.08 0.93 0.84 to 1.02
No high school diploma, % .031
 14 2,877 42.2 3,949 57.9 1.00 1.00
14 to 19.9 4,129 40.4 6,084 59.6 0.96 0.90 to 1.02 1.03 0.94 to 1.13
20 to 28.9 4,318 40.0 6,354 60.0 0.92 0.86 to 0.98 1.18 1.07 to 1.29
 29 6,618 42.0 9,264 58.0 1.00 0.93 to 1.07 1.17 1.05 to 1.30
Rural location .05
Yes 363 38.0 589 62.0 0.99 0.84 to 1.16 0.91 0.71 to 1.16
No 17,526 41.0 24,913 59.0 1.00 1.00
Tumor grade  .001
Well differentiated 3,496 50.0 3,492 50.0 1.00 1.00
Moderately differentiated 9,968 34.0 19,182 66.0 0.69 0.65 to 0.74 1.38 1.23 to 1.54
Poorly differentiated 1,236 35.6 2,234 61.4 0.80 0.72 to 0.88 2.10 1.81 to 2.44
Unknown 4,261 66.6 2,135 33.4 1.62 1.48 to 1.77 0.72 0.61 to 0.85
T classification  .001
pT1 9,431 46.5 10,854 53.5 1.00 1.00
pT2 2,920 16.8 14,461 83.2 0.26 0.25 to 0.27 3.96 3.64 to 4.30
Margins  .001
Positive or unknown 4,494 23.7 1,430 5.3 3.14 2.76 to 3.58
Negative 14,467 76.3 25,613 94.7 1.00
Surgery
Local excision 5.19 4.78 to 5.63
Proctectomy 1.00
Comorbidity score  .001
0 8,925 45.5 10,708 54.5 1.00 1.00
1 1,610 37.6 2,676 62.4 0.76 0.70 to 0.83 0.83 0.73 to 0.96
2 492 39.2 764 60.8 0.81 0.70 to 0.93 0.67 0.52 to 0.86
Abbreviations: LE, local excision; OR, odds ratio; RT, radiation therapy.
ORs for comorbidity score based on subset analysis using 2003 to 2010 incident patient cases only (n  25,175).
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OS than those undergoing proctectomy alone or LE plus irradiation
(Fig 4). In the subset analysis of years 2003 to 2005, controlling for
comorbidity score, adjusted OS for all four treatment groups was
equivalent. For T2N0 patient cases, adjusted OS among patients
treated with proctectomy alone, proctectomy plus irradiation, and LE
plus irradiation were equivalent. Meanwhile, patients treated with LE
alone had significantly poorer adjusted OS, even after controlling for
comorbidity score.
Sensitivity Analyses
Because of the lack of mesenteric resection, there may have been
understaging in the LE group; however, there was essentially no
change in the hazard ratio of death when the proctectomy comparison
group was changed from T1N0/T2N0 to T1Nany/T2Nany. Patients
with T2 tumors undergoing LE still had statistically inferior survival
(Data Supplement). Additionally, because low rectal cancers have
higher rates of recurrence but often require abdominoperineal resec-
tion, we examined whether preferential use of LE for low-risk cancers
might explain inferior survival. However, limiting the proctectomy
group to those treated with abdominoperineal resection yielded sim-
ilar results, with the only statistically significant difference in survival
being poorer OS for patients with T2N0 disease treated with LE
(Data Supplement).
DISCUSSION
Tumor resection along with TME is the standard of care surgical
treatment for the vast majority of rectal cancers.6,7 The incidence of
radiographically occult nodal metastasis ranges from 6% for low-risk
T1 tumors to as high as 65% for poorly differentiated T2 tumors with
lymphovascular invasion.5 As a result, by including complete nodal
clearance, TME optimizes locoregional control and tumor staging.
TME has been demonstrated to lower the rate of local recurrence,
limiting the long-term morbidity and mortality of rectal cancer. Still,
TME is associated with substantial morbidity, so alternative ap-
proaches to management of rectal cancer continue to be explored.
LE, via traditional TAE or TEMS, removes the full thickness of
bowel wall with grossly negative margins but yields few if any lymph
nodes for pathologic evaluation. The potential advantages of LE are
lower morbidity rates and better long-term functional outcomes.12 In
particular, for distal rectal tumors, LE offers the promise of sphincter
preservation, whereas TME often results in permanent ostomy cre-
ation. Although the long-term functional outcomes after LE have not
been systematically examined, it is likely that bowel, urinary, and
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Fig 3. Adjuvant radiation therapy use for stage I rectal cancers by T stage and
type of surgical procedure. LE, local excision.
Table 2. Adjusted OS for Patients With Stage I Rectal Cancer Diagnosed
From 1998 to 2005
Characteristic
T1 T2
HR 95% CI T2 95% CI
Sex
Male 1.00 1.00
Female 0.76 0.71 to 0.81 0.78 0.73 to 0.82
Age, years
 30 1.38 0.61 to 3.09 0.64 0.21 to 2.00
30 to 39 0.87 0.59 to 1.28 0.56 0.37 to 0.86
40 to 49 0.77 0.61 to 0.97 0.75 0.62 to 0.91
50 to 59 1.00 1.00
60 to 69 1.73 1.50 to 1.99 1.35 1.19 to 1.52
70 to 79 3.13 2.71 to 3.62 2.74 2.42 to 3.10
80 to 89 6.84 5.88 to 7.96 5.23 4.60 to 5.96
 90 14.33 11.40 to 18.05 9.02 7.38 to 11.02
Race
White 1.00 1.00
Black 1.30 1.43 to 1.50 1.29 1.13 to 1.47
Native American 1.29 0.64 to 2.59 2.11 1.09 to 4.08
Asian 0.68 0.51 to 0.91 0.84 0.67 to 1.06
Other/unknown 0.74 0.55 to 0.99 0.87 0.66 to 1.14
Insurance
Uninsured 1.30 0.92 to 1.84 1.34 1.02 to 1.77
Private 1.00 1.00
Medicaid 1.60 1.22 to 2.11 1.67 1.34 to 2.07
Medicare 1.46 1.33 to 1.60 1.17 1.08 to 1.27
No high school diploma, %
 14 1.00 1.00
14 to 19.9 1.10 1.01 to 1.20 1.12 1.04 to 1.21
20 to 28.9 1.16 1.06 to 1.27 1.18 1.09 to 1.27
 29 1.24 1.12 to 1.38 1.19 1.08 to 1.30
Rural location
Yes 0.96 0.76 to 1.21 0.88 0.73 to 1.08
No 1.00 1.00
Tumor grade
Well differentiated 1.00 1.00
Moderately differentiated 1.02 0.93 to 1.11 1.06 0.96 to 1.17
Poorly differentiated 1.07 0.92 to 1.25 1.12 0.98 to 1.28
Unknown 0.92 0.81 to 1.03 0.95 0.80 to 1.13
Margins
Positive or unknown 1.25 1.13 to 1.38 1.22 1.11 to 1.35
Negative 1.00 1.00
Treatment
LE alone 1.19 1.10 to 1.28 1.39 1.26 to 1.53
Proctectomy alone 1.00 1.00
LE plus RT 1.17 0.71 to 1.92 0.96 0.66 to 1.38
Proctectomy plus RT 1.28 1.06 to 1.54 1.00 0.91 to 1.11
Comorbidity score
0 1.00 1.00
1 1.52 1.30 to 1.79 1.56 1.36 to 1.80
2 2.82 2.24 to 3.54 2.49 2.03 to 3.06
Abbreviations: HR, hazard ratio; LE, local excision; RT, radiation therapy.
HRs for comorbidity score based on subset analysis using 2003 to 2005
incident patient cases only.
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sexual function are superior compared with outcomes after TME.
However, locoregional recurrence rates after LE are high (10% to
22%), primarily because of occult nodal disease.3,10,13 As a result,
LE is currently considered an acceptable definitive surgical proce-
dure only for T1N0 rectal cancers that are  3 cm in size, are well to
moderately differentiated, and do not involve lymphovascular or
perineural invasion.6,7
Because local recurrences may be amenable to salvage surgical
therapy, differences in local recurrence rates may not translate into
differences in OS. However, salvage surgical resection is not possible
for all recurrences, and salvage procedures generally result in morbid-
ity beyond that associated with TME alone.14-16 Even with multimo-
dality therapy, in one study, treatment of local recurrences required
multivisceral pelvic resection in 33% of patients and total pelvic exen-
teration in 5%.14
Still, the importance of quality of life versus potential risk of
recurrence will be valued differently by different patients. As a result, it
is reasonable to continue to seek to identify additional groups of
patients who might be adequately treated with an LE approach.5,17
This is especially true for patients with T1 tumors, because survival
differences between patients treated with LE and those treated with
proctectomy seem to be negligible.
The addition of chemoradiotherapy has been proposed to im-
prove oncologic control with LE.8,9 Although early studies are prom-
ising with regard to oncologic control, it is unknown whether urinary,
sexual, and GI morbidity associated with irradiation may mitigate
some of the functional advantages of LE.8,9 As a result, the role of
adjuvant chemoradiotherapy for stage I tumors remains unclear. A
study of multimodality therapy from Italy, which used a more exten-
sive transanal resection that included resection of adjacent mesenteric
tissue, showed promising local control rates (12% local recurrence at
10 years).9 In the United States, a recent American College of Surgeons
Oncology Group trial (ACOSOG Z6041) demonstrated an excellent
pathologic complete response rate (44%) for the primary tumor in
clinically staged T2 rectal cancers after neoadjuvant capecitabine/
oxaliplatin and irradiation, but there were high rates of toxicity during
chemoradiotherapy.8 Our study showed OS for both T1 and T2 tu-
mors treated with LE followed by irradiation was similar to survival for
similar patients treated with proctectomy alone. However, these re-
sults should be interpreted with caution, because the numbers of
patients were small, and registry data permit adjustment for only a
limited number of covariates. Still, the evidence suggests that patients
with stage I rectal cancer treated with LE in combination with chemo-
radiotherapy may have oncologic outcomes similar to those of pa-
tients treated with TME alone.
The prior NCDB study examining patterns of surgical care for
rectal cancer brought attention to the steady climb in rates of LE for
stage I tumors.10 Use of LE continues to increase for all stage I tumors,
with 62% of all T1 and 21% of all T2 cancers treated with LE in 2010.
Given the promising early results of multimodality therapy, one might
have speculated that the increase in LE over the past decade would be
accompanied by a parallel increase in use of radiation therapy.8,9
However, use of adjuvant radiation for stage I rectal cancer declined
over the study period. Although some of this decrease may be related
to a shift in paradigm to neoadjuvant therapy, it is clear that use of LE
as a single-modality therapy is increasing.
The reasons that rates of LE are increasing for higher-risk tumors
that do not meet guideline criteria for LE are unclear.6,7 The trend may
be patient driven, with more patients demanding therapies with min-
imal impact on quality of life.18,19 Alternatively, providers may not be
aware of the guideline criteria for LE (mobile,  3 cm, well or moder-
ately differentiated T1 tumors;  30% of bowel circumference with-





































































Fig 4. Adjusted overall survival by treatment group for T1N0 tumors from (A) 1998 to 2005 (n  11,528) and (B) 2003 to 2005 (includes comorbidity adjustment; n 
4,295) and for T2N0 tumors from (C) 1998 to 2005 (n  11,564) and (D) 2003 to 2005 (includes comorbidity adjustment; n  3,545). HR, hazard ratio.
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describing TEMS may lead some surgeons to push the limits of indi-
cations for this approach.19-24 This type of technology-driven, rather
than data-driven, evolution in practice patterns has been observed for
other cancers.25 Regardless of the reasons for these changes, the data
from this study should be cautionary to those considering an LE
approach to management of T2 rectal cancer, because patients with T2
tumors who undergo LE alone have statistically significantly poorer
oncologic outcomes than patients treated with proctectomy.10
Our study has limitations: registry data provide little detail re-
garding therapeutic interventions and oncologic outcomes, the data
offer limited detail about surgical procedure performed, and some
data on first course of therapy may have been missing, such that a
patient could have undergone a subsequent surgical procedure or
adjuvant therapy after LE that was not captured. The result of this
error would be a bias toward the mean, pushing survival curves be-
tween the surgical groups closer together than they may actually be. In
other words, the differences in outcome between proctectomy and LE
groups may be even more substantial than found in this study. Infor-
mation on rates of local recurrence, salvage surgical procedures, and
disease-specific survival is important but cannot be obtained without
augmentation of the NCDB through other sources, such as the med-
ical record abstraction completed for the prior study.10 Finally, the
reasons why interventions were or were not performed are also un-
known. This is demonstrated by the subset of patients who received
adjuvant radiation therapy after proctectomy for T1N0 tumors. Be-
cause irradiation would not be routinely recommended for these
patients, some unmeasured factor may have influenced treatment
choice and outcome for these patients. Similarly, the surprising find-
ing that LE was less common for patients with higher comorbidity
scores could not be further explored. Ultimately, the inherent selec-
tion bias when comparing LE with proctectomy could only be mini-
mally controlled for using the NCDB.
In conclusion, despite the limitations and inherent selection bias
of registry data, this study clearly demonstrates rising rates of LE for
treatment of stage I rectal cancer. Additional investigation is war-
ranted to understand why a growing proportion of patients with stage
I disease are treated in this manner and to ensure that novel treatment
paradigms are properly applied in practice.6,7
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS
OF INTEREST
The author(s) indicated no potential conflicts of interest.
AUTHOR CONTRIBUTIONS
Conception and design: Karyn B. Stitzenberg, Michael O. Meyers
Collection and assembly of data: Karyn B. Stitzenberg
Data analysis and interpretation: All authors
Manuscript writing: All authors
Final approval of manuscript: All authors
REFERENCES
1. MacFarlane JK, Ryall RD, Heald RJ: Mesorec-
tal excision for rectal cancer. Lancet 341:457-460,
1993
2. Bleier JI, Maykel JA: Outcomes following
proctectomy. Surg Clin North Am 93:89-106, 2013
3. You YN: Local excision: Is it an adequate
substitute for radical resection in T1/T2 patients?
Semin Radiat Oncol 21:178-184, 2011
4. Nash GM, Weiser MR, Guillem JG, et al:
Long-term survival after transanal excision of T1
rectal cancer. Dis Colon Rectum 52:577-582, 2009
5. Saraste D, Gunnarsson U, Janson M: Predict-
ing lymph node metastases in early rectal cancer.
Eur J Cancer 49:1104-1108, 2013
6. Tjandra JJ, Kilkenny JW, Buie WD, et al:
Practice parameters for the management of rectal
cancer (revised). Dis Colon Rectum. 48:411-423,
2005
7. National Comprehensive Cancer Network:
NCCN Clinical Practice Guidelines in Oncology: Rec-
tal Cancer—Version 4.2013. Fort Washington, PA,
National Comprehensive Cancer Network, 2012
8. Garcia-Aguilar J, Shi Q, Thomas CR Jr, et al: A
phase II trial of neoadjuvant chemoradiation and
local excision for T2N0 rectal cancer: Preliminary
results of the ACOSOG Z6041 trial. Ann Surg Oncol
19:384-391, 2012
9. Lezoche E, Baldarelli M, Lezoche G, et al:
Randomized clinical trial of endoluminal locoregional
resection versus laparoscopic total mesorectal exci-
sion for T2 rectal cancer after neoadjuvant therapy.
Br J Surg 99:1211-1218, 2012
10. You YN, Baxter NN, Stewart A, et al: Is the
increasing rate of local excision for stage I rectal
cancer in the United States justified? A nationwide
cohort study from the National Cancer Database.
Ann Surg 245:726-733, 2007
11. American College of Surgeons: NCDB Participant
User File: AJCC Pathologic T. http://ncdbpufbeta.facs
.org/?qcontent/ajcc-pathologic-t
12. Doornebosch PG, Tollenaar RA, Gosselink
MP, et al: Quality of life after transanal endoscopic
microsurgery and total mesorectal excision in early
rectal cancer. Colorectal Dis 9:553-558, 2007
13. Allaix ME, Arezzo A, Giraudo G, et al:
Transanal endoscopic microsurgery vs. laparoscopic
total mesorectal excision for T2N0 rectal cancer.
J Gastrointest Surg 16:2280-2287, 2012
14. You YN, Roses RE, Chang GJ, et al: Multimo-
dality salvage of recurrent disease after local
excision for rectal cancer. Dis Colon Rectum. 55:
1213-1219, 2012
15. Stipa F, Giaccaglia V, Burza A: Management
and outcome of local recurrence following transanal
endoscopic microsurgery for rectal cancer. Dis Co-
lon Rectum 55:262-269, 2012
16. Doornebosch PG, Ferenschild FT, de Wilt JH,
et al: Treatment of recurrence after transanal endo-
scopic microsurgery (TEM) for T1 rectal cancer. Dis
Colon Rectum 53:1234-1239, 2010
17. Chang HC, Huang SC, Chen JS, et al: Risk
factors for lymph node metastasis in pT1 and pT2
rectal cancer: A single-institute experience in 943
patients and literature review. Ann Surg Oncol 19:
2477-2484, 2012
18. Temple LK, Naimark D, McLeod RS: Decision
analysis as an aid to determining the management
of early low rectal cancer for the individual patient.
J Clin Oncol 17:312-318, 1999
19. De Graaf EJ, Doornebosch PG, Tollenaar RA,
et al: Transanal endoscopic microsurgery versus
total mesorectal excision of T1 rectal adenocarcino-
mas with curative intention. Eur J Surg Oncol 35:
1280-1285, 2009
20. Wu Y, Wu YY, Li S, et al: TEM and con-
ventional rectal surgery for T1 rectal cancer: A
meta-analysis. Hepatogastroenterology 58:364-
368, 2011
21. Ramirez JM, Aguilella V, Valencia J, et al:
Transanal endoscopic microsurgery for rectal can-
cer: Long-term oncologic results. Int J Colorectal Dis
26:437-443, 2011
22. Baatrup G, Breum B, Qvist N, et al: Transanal
endoscopic microsurgery in 143 consecutive pa-
tients with rectal adenocarcinoma: Results from a
Danish multicenter study. Colorectal Dis 11:270-
275, 2009
23. Guerrieri M, Baldarelli M, Organetti L, et al:
Transanal endoscopic microsurgery for the treat-
ment of selected patients with distal rectal cancer:
15 years experience. Surg Endosc 22:2030-2035,
2008
24. Zieren J, Paul M, Menenakos C: Transanal
endoscopic microsurgery (TEM) vs. radical surgery
(RS) in the treatment of rectal cancer: Indications,
limitations, prospectives: A review. Acta Gastroen-
terol Belg 70:374-380, 2007
25. Stitzenberg KB, Wong YN, Nielsen ME, et al:
Trends in radical prostatectomy: Centralization, ro-




4282 © 2013 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
